Biochemical Safety of Ablative Yttrium-90 Radioembolization for Hepatocellular Carcinoma as a Function of Percent Liver Treated

被引:14
|
作者
De la Garza-Ramos, Cynthia [1 ]
Overfield, Cameron J. [1 ]
Montazeri, S. Ali [2 ]
Liou, Harris [1 ]
Paz-Fumagalli, Ricardo [1 ]
Frey, Gregory T. [1 ]
McKinney, J. Mark [1 ]
Ritchie, Charles A. [1 ]
Devcic, Zlatko [1 ]
Lewis, Andrew R. [1 ]
Harnois, Denise M. [3 ]
Patel, Tushar [3 ]
Toskich, Beau B. [1 ]
机构
[1] Mayo Clin Florida, Div Intervent Radiol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA
[2] Mayo Clin Arizona, Alix Sch Med, Scottsdale, AZ USA
[3] Mayo Clin Florida, Dept Transplant, Jacksonville, FL 32224 USA
关键词
hepatocellular carcinoma; radioembolization; Y-90; adverse events; RADIATION SEGMENTECTOMY; MULTICENTER; SURVIVAL; THERAPY;
D O I
10.2147/JHC.S319215
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Transarterial radioembolization can serve as an ablative therapy for early-stage hepatocellular carcinoma (HCC). Given the volumetric variability of liver segments, this study aimed to characterize the safety of ablative radioembolization by determining percent liver treated (%LT) thresholds associated with biochemical toxicity. Patients and Methods: Patients with HCC receiving a single ablative radioembolization treatment using glass microspheres from 2017 through 2020 were reviewed. %LT was calculated as treatment angiosome volume divided by whole liver volume. Biochemical toxicities were defined as increases in Albumin-Bilirubin (ALBI) grade or Child-Pugh (CP) class compared to baseline and albumin or bilirubin adverse events (AEs) per the Common Terminology Criteria for Adverse Events. Receiver operating characteristic curves and multivariate logistic regression analyses were performed to assess the impact of %LT on toxicities. Results: Of 141 patients analyzed, 53% (n=75) were ALBI 1, 45% (n=64) ALBI 2, 79% (n=111) CP-A, and 21% (n=30) CP-B. A %LT >= 14.5% was associated with grade/class increases in ALBI 2 (p <= 0.01) and CP-B patients (p=0.026). In multivariate analysis, a %LT >= 14.5% was an independent predictor of increases in the ALBI 2 and CP-B groups (p<0.01). No significant %LT threshold was found for ALBI 1 and CP-A patients. No grade 3/4 albumin or bilirubin AEs were reported, while grade 2 AEs were related to an initial whole liver volume <1.3 L (p <= 0.01). Conclusion: Patients with ALBI 2 and CP-B liver function are less likely to have an increase in their respective grade/class when treating <14.5% of the liver using glass microspheres. ALBI 1 and CP-A patients showed no definitive %LT threshold for biochemical toxicity within the range of this study.
引用
收藏
页码:861 / 870
页数:10
相关论文
共 50 条
  • [41] The MAAPE score in intermediate and advanced hepatocellular carcinoma treated with Yttrium-90 resin microsphere radioembolization
    Wallace, Michael C.
    Samuelson, Shaun
    Khoo, Tiffany
    Ooi, Jacob
    Tibballs, Jonathan
    Ferguson, John
    Preen, David B.
    Knuiman, Matthew
    Garas, George
    MacQuillan, Gerry
    Adams, Leon A.
    Jeffrey, Gary P.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (11) : 1945 - 1952
  • [42] Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma
    Salman, A.
    Simoneau, E.
    Hassanain, M.
    Chaudhury, P.
    Boucher, L. M.
    Valenti, D.
    Cabrera, T.
    Nudo, C.
    Metrakos, P.
    CURRENT ONCOLOGY, 2016, 23 (05) : E472 - E480
  • [43] Treating and Downstaging Hepatocellular Carcinoma in the Caudate Lobe with Yttrium-90 Radioembolization
    Saad M. Ibrahim
    Laura Kulik
    Talia Baker
    Robert K. Ryu
    Mary F. Mulcahy
    Michael Abecassis
    Riad Salem
    Robert J. Lewandowski
    CardioVascular and Interventional Radiology, 2012, 35 : 1094 - 1101
  • [44] Radioembolization with yttrium-90 glass microspheres for patients with hepatocellular carcinoma: a review
    Schlaak, Joerg Friedrich
    HEPATIC ONCOLOGY, 2014, 1 (04) : 387 - 393
  • [45] Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma
    Johnson, Guy E.
    Monsky, Wayne L.
    Valji, Karim
    Hippe, Daniel S.
    Padia, Siddharth A.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2016, 27 (08) : 1123 - 1129
  • [46] Yttrium-90 radioembolization-induced abscopal effect on hepatocellular carcinoma
    Steinhoff, Karen Geva
    Petersen, Tim-Ole
    Purz, Sandra
    Veelken, Rhea
    Van Boemmel, Florian
    Denecke, Timm
    Berg, Thomas
    Sabri, Osama
    JOURNAL OF DIGESTIVE DISEASES, 2022, 23 (04) : 237 - 239
  • [47] Treating and Downstaging Hepatocellular Carcinoma in the Caudate Lobe with Yttrium-90 Radioembolization
    Ibrahim, Saad M.
    Kulik, Laura
    Baker, Talia
    Ryu, Robert K.
    Mulcahy, Mary F.
    Abecassis, Michael
    Salem, Riad
    Lewandowski, Robert J.
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2012, 35 (05) : 1094 - 1101
  • [48] Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
    Nabrinsky, Edward
    James, Edward
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (05)
  • [49] Segmental yttrium-90 radioembolization versus chemoembolization for localized hepatocellular carcinoma
    Padia, Siddharth A.
    Johnson, Guy E.
    Horton, Kathryn Jors
    Kwan, Sharon
    Vaidya, Sandeep
    Ingraham, Christopher R.
    Monsky, Wayne L.
    Valji, Karim
    Kogut, Matthew J.
    Yeung, Raymond Sze
    Park, James
    Bhattacharya, Renuka
    Liou, Iris
    Harris, William Proctor
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Benign Biliary Stricture after Yttrium-90 Radioembolization for Hepatocellular Carcinoma
    Kim, Hyo-Cheol
    Joo, Ijin
    Lee, Myungsu
    Chung, Jin Wook
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2020, 31 (12) : 2014 - 2021